Target Price | €185.50 |
Price | €148.50 |
Potential | 24.92% |
Number of Estimates | 16 |
16 Analysts have issued a price target Merck 2026 . The average Merck target price is €185.50. This is 24.92% higher than the current stock price. The highest price target is €208.00 40.07% , the lowest is €160.00 7.74% . | |
A rating was issued by 18 analysts: 15 Analysts recommend Merck to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Merck stock has an average upside potential 2026 of 24.92% . Most analysts recommend the Merck stock at Purchase. |
15 Analysts have issued a sales forecast Merck 2024 . The average Merck sales estimate is €21.1b . This is 0.77% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €21.3b 1.80% , the lowest is €21.0b 0.00% .
This results in the following potential growth metrics:
2023 | €21.0b | 5.57% |
---|---|---|
2024 | €21.1b | 0.63% |
2025 | €22.1b | 4.73% |
2026 | €23.1b | 4.40% |
2027 | €24.1b | 4.48% |
2028 | €25.2b | 4.31% |
15 Analysts have issued an Merck EBITDA forecast 2024. The average Merck EBITDA estimate is €6.0b . This is 6.26% lower than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €6.1b 4.55% , the lowest is €5.8b 9.52% .
This results in the following potential growth metrics and future EBITDA Margins:
2023 | €5.8b | 14.26% |
---|---|---|
2024 | €6.0b | 3.45% |
2025 | €6.5b | 8.13% |
2026 | €6.9b | 6.54% |
2027 | €7.3b | 4.75% |
2028 | €7.7b | 5.58% |
2023 | 27.75% | 9.20% |
---|---|---|
2024 | 28.52% | 2.78% |
2025 | 29.45% | 3.26% |
2026 | 30.05% | 2.04% |
2027 | 30.13% | 0.27% |
2028 | 30.50% | 1.23% |
12 Merck Analysts have issued a net profit forecast 2024. The average Merck net profit estimate is €2.9b . This is 8.44% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €3.1b 16.13% , the lowest is €2.8b 4.35% .
This results in the following potential growth metrics and future Net Margins:
2023 | €2.8b | 15.03% |
---|---|---|
2024 | €2.9b | 3.44% |
2025 | €3.4b | 17.89% |
2026 | €3.8b | 9.01% |
2027 | €4.1b | 8.41% |
2028 | €4.4b | 8.57% |
2023 | 13.46% | 10.02% |
---|---|---|
2024 | 13.84% | 2.81% |
2025 | 15.58% | 12.57% |
2026 | 16.27% | 4.43% |
2027 | 16.88% | 3.75% |
2028 | 17.57% | 4.09% |
12 Analysts have issued a Merck forecast for earnings per share. The average Merck <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is €6.72 . This is 8.39% higher than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is €7.20 16.13% , the lowest is €6.47 4.35% .
This results in the following potential growth metrics and future valuations:
2023 | €6.50 | 15.03% |
---|---|---|
2024 | €6.72 | 3.38% |
2025 | €7.93 | 18.01% |
2026 | €8.64 | 8.95% |
2027 | €9.37 | 8.45% |
2028 | €10.17 | 8.54% |
Current | 23.95 | 2.26% |
---|---|---|
2024 | 22.09 | 7.77% |
2025 | 18.73 | 15.21% |
2026 | 17.19 | 8.22% |
2027 | 15.85 | 7.80% |
2028 | 14.60 | 7.89% |
Based on analysts' sales estimates for 2024, the Merck stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of 3.45 and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of 3.06 .
This results in the following potential growth metrics and future valuations:
Current | 3.48 | 2.52% |
---|---|---|
2024 | 3.45 | 0.88% |
2025 | 3.29 | 4.52% |
2026 | 3.15 | 4.21% |
2027 | 3.02 | 4.29% |
2028 | 2.89 | 4.14% |
Current | 3.08 | 2.63% |
---|---|---|
2024 | 3.06 | 0.77% |
2025 | 2.92 | 4.52% |
2026 | 2.80 | 4.21% |
2027 | 2.68 | 4.29% |
2028 | 2.56 | 4.14% |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.